Overview

• Under an extensive review begun in February, HHS canceled 22 BARDA-funded mRNA vaccine contracts worth about $500 million.
• Kennedy stated that data show mRNA platforms do not protect effectively against upper respiratory infections such as COVID-19 and influenza.
• The department will invest in whole-virus vaccines and other non-mRNA approaches designed to retain potency against mutating pathogens.
• Some late-stage BARDA projects and ongoing NIH mRNA research will remain in place to preserve prior scientific and taxpayer investments.
• Public health experts warn the decision risks eroding rapid vaccine development capabilities critical for responding to future pandemics.